Basse Gloria F 4

What Happened
Gloria F. Basse, a director of Immucell Corp (ICCC), was granted a derivative award of 10,000 shares on April 16, 2025. The grant was reported as an acquisition (award) with an acquisition price of $0.00, i.e., no cash was paid by the insider. The issuer states the options were granted as compensation for board services.

Key Details

• Transaction date: 2025-04-16 (Period of Report)
• Filing date (Form 4): 2026-04-14 (appears to be filed late relative to the transaction)
• Transaction type/code: Award/Grant (A) — derivative instrument (options)
• Shares/options granted: 10,000; acquisition price reported $0.00; reported dollar value $0 (grant)
• Shares owned after transaction: not disclosed in the provided filing details
• Footnotes/notes: Issuer remarks state the options were granted to compensate directors; no mention of a 10b5-1 plan, tax withholding, immediate sale, or vesting schedule in the supplied information

Context
Director awards are a common form of non-cash compensation and do not necessarily signal the director buying or selling stock. Because this filing was submitted nearly a year after the reported grant date, the information is less timely than typical Form 4 reporting (which is normally due within two business days of the transaction). Derivative grants like this typically vest over time and may carry exercise terms; those specifics were not included in the provided summary.